Company / Interest Expense
ROCKET PHARMACEUTICALS, INC. Interest Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$1.9M
FY2025
5-year range
$1.9M / $7.0M
FY2021-FY2025
Trend
+1.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense returned to growth in FY2025 after 2 years of decline, reaching $2M.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -20.8%.
Improved from $3M to $2M over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -35.3%
- 5-Year CAGR
- -20.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -20.8%, indicating a declining trend.
- In FY2025, interest expense increased 1.3% year-over-year.
- Peak interest expense was recorded in FY2022.
- Lowest interest expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.9M | +1.3% |
| FY2024 | $1.9M | -37.5% |
| FY2023 | $3.0M | -57.3% |
| FY2022 | $7.0M | +16.9% |
| FY2021 | $6.0M | -1.3% |
| FY2020 | $6.0M | +0.0% |
| FY2019 | $6.0M | - |
| FY2018 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026